Abstract #606 High Efficacy of 8 Weeks of Ledipasvir/Sofosbuvir in African Americans with HCV – Whitney Nichols, et al.
Study Aims and Results: Current HCV guidelines (www.hcvguidelines.org) recommend that African Americans with genotype 1 HCV receive 12 weeks of ledipasvir/sofosbuvir (LDV/SOF), even if they meet criteria for 8 weeks. Research shows conflicting results of treatment outcomes in this group. This retrospective study evaluated the efficacy of 8 weeks of LDV/SOF in African Americans in a real-world setting.
Using data from 2014 to 2017, researchers analyzed data from 59 participants, comparing age, fibrosis level, gender, genotype, medication/treatment adherence, and use of acid-reducing medicines. When comparing 8 weeks to 12 weeks of treatment, they found no significant differences between groups regarding age, genotype, medication and appointment adherence and acid-reducing medication use. However, there were more females, earlier liver fibrosis, and lower baseline viral loads in the 8-week group.
Conclusions: In a real-world setting, 8 weeks of HCV treatment showed good results in African Americans.
Editorial Comments: This study is small and retrospective. I would not rely on these findings to make treatment decisions. I hope we see some large prospective research on this subject. Click here to read the entire abstract and view the poster.Share This Page